284 related articles for article (PubMed ID: 25917991)
21. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
BMJ Open; 2016 Mar; 6(3):e009914. PubMed ID: 26966057
[TBL] [Abstract][Full Text] [Related]
22. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
Sandø N; Kofoed K; Zachariae C; Fouchard J
Acta Derm Venereol; 2014 May; 94(3):288-92. PubMed ID: 24150529
[TBL] [Abstract][Full Text] [Related]
23. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
24. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
[TBL] [Abstract][Full Text] [Related]
25. Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).
Cocchio S; Prandi GM; Furlan P; Bertoncello C; Fonzo M; Saia M; Baldovin T; Baldo V
BMC Infect Dis; 2020 Nov; 20(1):857. PubMed ID: 33208109
[TBL] [Abstract][Full Text] [Related]
26. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
Lamb F; Herweijer E; Ploner A; Uhnoo I; Sundström K; Sparén P; Arnheim-Dahlström L
BMJ Open; 2017 Jun; 7(6):e015021. PubMed ID: 28600369
[TBL] [Abstract][Full Text] [Related]
27. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
[TBL] [Abstract][Full Text] [Related]
28. Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?
Shum J; Kelsberg G; Safranek S
J Fam Pract; 2015 Sep; 64(9):581-3. PubMed ID: 26546954
[TBL] [Abstract][Full Text] [Related]
29. Knowledge of sexually transmitted HPV infection, genitoanal warts, cancer and their prevention among young females after vaccine introduction in Germany.
Kuznetsov AV; Müller RA; Ruzicka T; Herzinger T; Kuznetsov L
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1527-34. PubMed ID: 23216713
[TBL] [Abstract][Full Text] [Related]
30. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
31. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.
Blomberg M; Dehlendorff C; Munk C; Kjaer SK
Clin Infect Dis; 2013 Oct; 57(7):929-34. PubMed ID: 23804192
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
33. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
34. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
35. HPV vaccines: their pathology-based discovery, benefits, and adverse effects.
Nicol AF; de Andrade CV; Russomano FB; Rodrigues LS; Oliveira NS; Provance DW; Nuovo GJ
Ann Diagn Pathol; 2015 Dec; 19(6):418-22. PubMed ID: 26321154
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
[TBL] [Abstract][Full Text] [Related]
37. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
38. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus and vaccination.
Huang CM
Mayo Clin Proc; 2008 Jun; 83(6):701-6; quiz 706-7. PubMed ID: 18533087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
